Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 43

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 43
---
 300,000 additional shares of the Series B Preferred Stock within 30 days from the date of this prospectus supplement
solely to cover over-allotments at the public offering price less the underwriting discount. To the extent the option is exercised, each
underwriter must purchase a number of additional shares of the Series B Preferred Stock approximately proportionate to that underwriter’s
initial purchase commitment.

Listing

Prior to the Series B Preferred Stock offering,
there has been no public market for the Series B Preferred Stock. We intend to apply to list the Series B Preferred Stock on
the NYSE under the symbol “GMRE PrB.” If the application is approved, we expect trading of the Series B Preferred Stock
on the NYSE to begin within 30 days after the Series B Preferred Stock is first issued. The underwriters have advised us that they
intend to make a market in the Series B Preferred Stock prior to commencement of any trading on the NYSE. However, the underwriters
will have no obligation to do so, and we cannot assure you that a market for the Series B Preferred Stock will develop or be maintained
prior or subsequent to commencement of trading on the NYSE.

<div align='center'>S-25</div>

Underwriting Discounts and Expenses

The following table shows the underwriting discounts
and commissions that we will pay to the underwriters in connection with the Series B Preferred Stock offering. These amounts are
shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares of Series B Preferred
Stock.

|           |     | Paid by us | No Exercise |     |   | Full Exercise |
|:----------|:----|:-----------|------------:|:----|:--|--------------:|
| Per share |     | $          |      0.7875 |     | $ |        0.7875 |
| Total     |     | $          |   1,575,000 |     | $ |     1,811,250 |

We estimate that our expenses related to this
offering will be approximately $300,000, excluding the underwriting discount.

Price Stabilization and Short Positions

In connection with the offering, the underwriters
may purchase and sell shares of Series B Preferred Stock in the open market. Purchases and sales in the open market may include short
sales, purchases to cover short positions, which may include purchases pursuant to the option to purchase additional shares, and transactions
that